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BY-NC-ND license (http://creativecomBackground: Influenza viruses cause acute respiratory disease. Because of the high genetic
variability of viruses, effective vaccines and antiviral agents are limited. Considering the fact
that the site of influenza virus entry is the mucosa of the upper respiratory tract, probiotics
that can enhance mucosal immunity as well as systemic immunity could be an important source
of treatment against influenza infection.
Methods: Mice were fed with Lactobacillus rhamnosus M21 or skim milk and were challenged
with influenza virus. The resulting survival rate, lung inflammation, and changes in the cyto-
kine and secretory immunoglobulin A (sIgA) levels were examined.
Results: Because of infection (influenza virus), all the mice in the control group and 60% of the
mice in the L. rhamnosus M21 group died; however, the remaining 40% of the mice fed with L.
rhamnosus M21 survived the infection. Pneumonia was severe in the control group but moder-
ate in the group treated with L. rhamnosus M21. Although there were no significant changes in
the proinflammatory cytokines in the lung lysates of mice collected from both groups, levels of
interferon-g and interleukin-2, which are representative cytokines of type I helper T cells,
were significantly increased in the L. rhamnosus M21-treated group. An increase in sIgA as wellt of Veterinary Immunology, College of Veterinary Medicine, Konkuk University, 1 Hwayang-dong,
of Korea.
.kr (S.Y. Park).
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Effectiveness of L. rhamnosus M21 against influenza 17as the diminution of inflammatory cells in bronchoalveolar lavage fluid was also observed in the
L. rhamnosus M21-treated group.
Conclusion: These results demonstrate that orally administered L. rhamnosus M21 activates
humoral as well as cellular immune responses, conferring increased resistance to the host
against influenza virus infection.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Influenza is an acute viral respiratory infection that results
in high morbidity and significant mortality. There have been
10 influenza A pandemics in the past 300 years. Many ex-
perts are concerned that even a mild pandemic could kill
many millions of people1,2; as such, influenza has become
one of the most threatening infectious diseases for humans.
Influenza virus consists of eight single-stranded RNA seg-
ments, and is classified into subtypes based on antigenic
differences in two major surface glycoproteins, namely,
hemagglutinin (HA) and neuraminidase. It is recognized
that only three subtypes (H1, H2, and H3) of 15 HAs have
established stable lineage in humans.3 However, the H5,
H7, and H9 subtypes, which were initially thought to infect
only birds, were also recently isolated from humans,4,5
indicating the potential for influenza viruses to be trans-
ferred from bird populations to humans. The fact that other
subtypes could cross species barriers to infect humans has
provoked much concern that such infections could lead to
another influenza pandemic.6 Thus, the need for effective
control against influenza virus infection is critical.
In general, prevention is more effective than therapeu-
tic treatment in protecting hosts from viral infections.
However, the development of effective preventive vaccines
against influenza virus has been hampered due to its high
genetic variability.7 Moreover, the effectiveness of antiviral
drugs therapy is also hindered by the development of drug-
resistant viruses; in addition, the use of such drugs is
limited owing to their severe side effects. Thus, there has
been a continued search for alternative ways to control
influenza infection, and probiotics have emerged as a
strong candidate.
Probiotics are live microorganisms that confer health
benefits to the host when administered in appropriate
doses.8 Because the site of influenza virus entry is the
mucosa of the upper respiratory tract and one of the
beneficial properties of probiotics is enhancing mucosal
immunity, probiotics have long been recognized as an
important protective candidate against influenza infection.
For example, some strains of Lactobacillus or Bifidobacte-
rium have been shown to have protective potential against
influenza infection in animals.9e11
We have previously reported that intranasal12 as well as
sublingual13 administration of Lactobacillus rhamnosus M21
ameliorated influenza infection in mice by enhancing
mucosal immunity. Although we demonstrated the anti-
influenza activity of L. rhamnosus M21 through these
studies, nasal as well as sublingual administration ofprobiotics has limitations in terms of practical application
to the host. Probiotics are usually consumed by eating or
drinking. In this regard, it is necessary to prove that L.
rhamnosus M21 can maintain its anti-influenza activity
when exposed to strong acids in the stomach upon oral
administration. The aims of the present study were there-
fore to investigate whether orally administered L. rham-
nosus M21 could provide the host beneficial effects against
influenza virus infection as well as to reveal responsible
immunological mechanisms.
Materials and methods
Mice and L. rhamnosus M21
Specific pathogen-free, female BALB/c mice (age, 4 weeks;
weight, 16e18 g) were purchased from Orient Bio
(Gapyeong, Gyeonggi, Korea). The mice were divided into
the following two groups: the experimental group, which
received oral administration of 0.3 mL of 1  109 colony
forming units/mL of L. rhamnosus M21 (KCTC 10965BP)
daily for 2 weeks; and the control group that received the
same volume of 5% skim milk, which was treated for 30
minutes at 63C to destroy any possible bacteria. Adminis-
tration of L. rhamnosus M21 or skim milk was continued
until termination of the experiment. All procedures con-
formed to the Guidelines for the Care and Use of Labora-
tory Animals of the Institutional Animal Care and Use
Committee of Konkuk University, Seoul, Korea. L. rhamno-
sus M21 was propagated in de Man, Rogosa, and Sharpe
(MRS; Difco, Sparks, MD, USA) broth at 37C for 24 hours.
The bacterial cells were then harvested by centrifugation
at 5,000  g for 10 minutes at 4C, and suspended in 5%
nonfat milk (Sigma-Aldrich, St. Louis, MO, USA). The cell
counts were determined on an MRS agar plate.
Influenza virus infection
Influenza virus A/NWS/3 3 (H1N1) was grown in the
chorioallantoic fluid of 10-day-old embryonic hen eggs.
After harvesting, the allantoic fluid was separated into al-
iquots and stored at 70C until use. On the day after oral
administration of L. rhamnosus M21 or skim milk for 2
weeks, lightly anesthetized mice were inoculated intrana-
sally with a 5.5 log10 50% tissue culture infectious dose of
influenza virus in 90 mL of phosphate-buffered saline (PBS).
For survival rate analysis, 10 mice/group were challenged
and observed daily after the infection for up to 20 days. For
Figure 1. Effect of Lactobacillus rhamnosus M21 treatment
on the survival rate of influenza virus-infected mice. Ten mice/
group were orally administered with skim milk (broken line) or
L. rhamnosus M21 (unbroken line) for 2 weeks and were
intranasally challenged with influenza virus. The survival rate
of each group was observed for 20 days.
18 J.A. Song et al.pathological analysis, on Day 3 and Day 6 after the infec-
tion, lung tissues were fixed in 10% buffered formalin for
routine hematoxylin and eosin (H&E) staining.
Cytokine analysis
To determine cytokine levels in the lung, lung tissues were
removed from noninfected and infected mice on Day 0, Day
1, Day 3, and Day 6 after the infection. Lung tissues were
homogenized in 1 mL of cold PBS, and centrifuged at
9,000  g at 4C for 30 minutes. The clarified cell lysates
were collected and their cytokine levels were determined
[interleukin-1b (IL-1b), IL-6, IL-4, IL-12, and interferon-g
(IFN-g)] using enzyme-linked immunosorbent assay kits
(R&D Systems, Minneapolis, MN, USA).
Analysis of bronchoalveolar lavage cells
Anesthetized mice were exsanguinated, and the chest
cavity was dissected to expose the trachea and lungs. A 24-
gauge catheter was inserted and secured in the trachea.
Lavage was performed twice by injecting 0.75 mL of pre-
warmed PBS into the lungs through the tracheal cannula.
Bronchoalveolar lavage (BAL) cells were concentrated by
centrifuging the lung fluid at 600 rpm for 5 minutes at 4C.
BAL cells were resuspended in 1 mL of PBS, cytospun,
stained with Diff-Quick (American Scientific Products,
McGaw Park, IL, USA), and counted using an ADAM auto-
matic cell counter (Digital Bio Technology, Seoul, Korea).
Determination of immunoglobulin A level in BAL
fluid
Total protein content in the BAL fluid was quantified by
Bradford reagent (Sigma-Aldrich). Plates were coated with
100 mL of 1 mg/mL purified immunoglobulin A (IgA) mono-
clonal antibody (Ab; BD Pharmingen, San Jose, CA, USA) by
incubating overnight at 4C. Blocking buffer, 300 mL [3%
bovine serum albumin (BSA) in PBS], was added and the
plates were incubated at room temperature for 2 hours.
BAL fluid and standard IgA (BD Pharmingen) were diluted
(1.5% BSA in PBS) and added to the plates, which were
incubated at room temperature for 2 hours. After washing
three times with 0.1% PBSeTween-20, the plates were
incubated with horseradish peroxidase-conjugated anti-IgA
Ab (dilution range, 1:25,000; Serotec, Raleigh, NC, USA) at
room temperature for 1 hour. The plates were developed
with 3,30,5,50-tetramethybenzidine (Chemicon Interna-
tional, Temecula, CA, USA). Reactions were terminated by
adding 100 mL of 2N H2SO4 and the optical density was read
at 450 nm.
Statistical analyses
Statistical significance of cytokine and IgA levels in the
lungs between groups were determined by one-way analysis
of variance and Duncan’s post hoc test. All data were pre-
sented as the statistical mean  standard error of the mean
and p < 0.05 was considered significant. Survival analysis
was performed using KaplaneMeier curves and log-rank test
with Bonferroni adjustment.Results
Survival rate of L. rhamnosus M21-fed mice
In the search for probiotics that can confer beneficial ef-
fects to the host against influenza infection, we evaluated
the efficiency of L. rhamnosus M21. When mice were
intranasally challenged with a lethal dose of influenza
virus, those fed with skim milk (control) began to die at Day
5 or Day 6, and by Day 17 all the mice had died. Although L.
rhamnosus M21-treated mice showed sickness on similar
days, approximately 40% survived the infection (Fig. 1). As
the surviving mice began to eat and drink thereafter and
completely recovered, we choose Day 20 as the terminal
point to demonstrate the significant difference between
groups. These experiments were repeated three times, and
all results were consistent. These results suggest that L.
rhamnosus M21 may be useful to confer the increased
resistance to the host against influenza virus infection,
which prompted us to investigate the underlying mecha-
nisms associated with the beneficial effects of this bacte-
rial strain.
Pathological analysis
To determine the relevance of pathological events occur-
ring in the lungs on survival rate, five mice in each group
were subjected to lung pathological analysis following
influenza virus infection. Up to Day 3 after the infection,
lungs from mice in the control and experiment groups
showed no changes compared with noninfected mice with
regard to gross lesions (data not shown). However, on Day
6, the lungs of all mice in the control group showed severe
pneumonia with massive hemorrhage (Fig. 2A), whereas the
lungs of the experimental group mice exhibited moderate
pneumonia with mild hemorrhage (Fig. 2B). H&E-stained
Figure 2. Effect of Lactobacillus rhamnosus M21 on acute pulmonary influenza virus infection. Mice were administered with skim
milk (A, C, and E) or L. rhamnosus M21 (B, D, and F) for 2 weeks and were intranasally infected with influenza virus. Six days after
the viral challenge, the lungs of the mice were removed for pathological analysis. Panels A and B show the gross changes of the
lungs. Panels CeF show the hematoxylin and eosin-stained sections with different magnifications (C and E, 40; D and F, 400).
Effectiveness of L. rhamnosus M21 against influenza 19tissue sections revealed that treatment with L. rhamnosus
M21 led to a significant reduction in influenza-induced lung
pathology. In the control group mice (i.e., mice infected
with influenza A virus and received skim milk treatment),
severe lung damages including extensive cellular infiltrates,
reduced alveolar spaces, hemorrhage, progressed fibrosis,
and alveolar edema were observed (Fig. 2C and E). By
contrast, the L. rhamnosus M21-treated mice showed
moderate pneumonia (Fig. 2D and F).
Infiltration of inflammatory cells in BAL
Although BAL cells do not represent all the infiltrated cells
in the lungs, they are commonly examined to reveal the
pathological states of the lungs. The total cell numbers in
the lungs started to increase at Day 3 and peaked on Day 6
after the infection (Fig. 3). The experimental group alsoshowed an increase in infiltrated cell numbers in the lungs,
but at a 19.7% lower level on average compared with the
control group. Although statistical significance between the
groups was not obtained due to high individual differences,
these data showed that the infiltration of inflammatory
cells into the lungs was reduced by administration of L.
rhamnosus M21. On Day 0, BAL cells mainly consisted of
macrophages and a few neutrophils. After Day 1, neutro-
phils started to increase, and became predominant on Day
3 when only a few lymphocytes were observed. On Day 6,
remarkable lymphocyte infiltration was seen (data not
shown).
Cytokine production in the lung
Because there is plenty of evidence supporting the fact that
cytokines influence the inflammatory response in influenza
Figure 3. Total cell numbers of bronchoalveolar lavage
(BAL). Mice were orally administered with skim milk (closed
triangles) or Lactobacillus rhamnosus MK21 (open squares) for
2 weeks and were intranasally infected with influenza virus.
Total cell numbers of BAL at the indicated days were counted
using an automatic cell counter. Each horizontal line repre-
sents the mean value for five mice.
Figure 4. Effect of Lactobacillus rhamnosus M21 treatment
on proinflammatory cytokines in lung lysates obtained after the
influenza virus challenge. Mice were orally administered with
skim milk (open squares) or L. rhamnosus MK21 (closed
squares) for 2 weeks and were intranasally infected with
influenza virus. (A) Interleukin-1b (IL-1b) and (B) IL-6 levels in
the lung lysate at the indicated days were determined with
enzyme-linked immunosorbent assay. Data are shown as
mean  standard error of the mean for each group (n Z 5).
20 J.A. Song et al.virus-infected lungs, we investigated whether administra-
tion of L. rhamnosus M21 could modulate the production of
cytokines. As shown in Fig. 4, 1 day after the infection, IL-
1b (Fig. 4A) and IL-6 (Fig. 4B) reached peak levels and
declined gradually thereafter, showing that an inflamma-
tory response was immediately induced by influenza virus
infection. However, there was no apparent difference be-
tween the experimental and control groups. Some pro-
biotics can affect the T-helper type 1 (Th1) and T-helper
type 2 (Th2) balance, thereby modulating disease out-
comes.14 In order to determine whether L. rhamnosus M21
shifts the Th1/Th2 paradigm, we investigated the levels of
IL-4 and IFN-g, representative cytokines of Th1 and Th2
cells, respectively. Whereas the level of IL-4 in the lungs
from both the control and experiment groups was too low
to detect (data not shown), the level of IFN-g started to
increase from Day 1 and was highest on Day 6 after the
infection. Even though the significant difference in the
level of IFN-g between the control group and the experi-
ment group on Day 6 vanished, the level of IFN-g in the
experimental group on Day 3 was three times higher than
that of the control group (Fig. 5A). We also examined IL-12
levels, another main cytokine of Th1 cells, which increased
greatly on Day 1 in the experimental group but not in the
control group, and found that it declined thereafter in both
groups (Fig. 5B).
IgA levels in BAL fluid
Early studies have shown that some probiotics administered
orally exhibit beneficial effects by production of secretory
IgA (sIgA).15 Therefore, the production of sIgA was exam-
ined in BAL fluid on Day 0, Day 1, Day 3, and Day 6 after the
infection. The sIgA levels started to increase in both groups
3 days after the infection, but the experimental group
showed a significant increase compared with the control
group on Day 6 after the infection (Fig. 6).
Discussion
In this study, we found that orally administered L. rham-
nosus M21 increased survival rate of mice that were lethallychallenged with influenza virus. Histopathological analysis
of the lungs confirmed the correlation between the
lethality and severity of the acute pneumonia. The infil-
tration of mononuclear cells in the lungs also decreased in
the experimental group. These results suggested that oral
administration of L. rhamnosus M21 inhibited the inflam-
matory response in the lungs after the influenza virus
infection. The significant increase in the IFN-g and IL-12
levels in the lungs of the mice in the experimental group
demonstrated that L. rhamnosus M21 shifted the type of
helper T cells to Th1, thereby enhancing the antiviral ac-
tivities. The levels of sIgA, a well-known frontline protector
against viral invasion, were also increased in the experi-
mental group. These results demonstrate that L. rhamnosus
Figure 5. Effect of Lactobacillus rhamnosus M21 on Th1-
derived cytokines in lung lysates after the influenza virus
challenge. Mice were orally administered with skim milk (open
squares) or L. rhamnosus MK21 (closed squares) for 2 weeks
and were intranasally infected with influenza virus. (A) Inter-
feron-g (IFN-g) and (B) interleukin-12 (IL-12) levels in the lung
lysate at the indicated days were determined with enzyme-
linked immunosorbent assay. Data are shown as
mean  standard error of the mean for each group (n Z 5).
Significant differences from the control group are denoted for
the L. rhamnosus-treated group (*p < 0.05).
Figure 6. Effect of Lactobacillus rhamnosus M21 on secre-
tory IgA (sIgA) levels in bronchoalveolar lavage (BAL) fluid after
the influenza virus challenge. Mice were orally administered
with skim milk (open squares) or L. rhamnosus MK21 (closed
squares) for 2 weeks and were intranasally infected with
influenza virus. The sIgA levels in BAL fluid at the indicated
days were determined with enzyme-linked immunosorbent
assay. Data are shown as mean  standard error of the mean
for each group (nZ 5). Significant differences from the control
group are denoted for the L. rhamnosus-treated group
(*p < 0.05).
Effectiveness of L. rhamnosus M21 against influenza 21M21 may be a useful probiotic for controlling influenza virus
infection.
It has been reported that one of the causes of death due
to influenza virus infection is the burst of inflammatory
cytokines. Although cytokines facilitate elimination of
pathogens, their excessive production can be harmful, in
part by causing excessive infiltration of inflammatory cells
into tissues, resulting in tissue destruction.6 Previous
studies have shown that the therapeutic effects of some
agents against influenza virus infection in mice were
attributed to a reduction in proinflammatory cytokines.16,17
Therefore, we evaluated whether administration of L.rhamnosus M21 could modulate inflammatory cytokine
production by measuring periodic changes in the levels of
IL-1 and IL-6 in the lungs. Our results showed that cytokines
levels peaked on Day 1 after the infection and declined
thereafter, which indicates that these cytokines are pri-
marily induced by influenza virus infection in the lung.
However, there was no significant difference between the
cytokines levels in the control and experiment groups,
indicating that the beneficial effect of L. rhamnosus M21
was not related to changes in the IL-1 and IL-6 levels. The
roles of IL-1 and IL-6 in the pathogenesis of influenza virus
infection are diverse. Although IL-1 is responsible for acute
lung pathology following influenza virus infection,18 most
IL-1-deficient mice died.19 Overproduction of IL-6 can be
detrimental to the host and has been associated with viral
pathogenesis.20 Physiologic symptoms, including fever and
body weight loss due to influenza virus infection, are
reduced in IL-6-deficient mice, indicating that IL-6 con-
tributes to the pathogenesis of influenza virus infection.21
However, IL-6 also appears to contribute to the develop-
ment of T-cell memory to influenza virus.22 It appears that
functional differences between IL-1 and IL-6 in relation to
lung pathogenesis following an episode of influenza virus
infection depend on a variety of factors including the
pathogenicity, challenge dose, and other characteristics of
the influenza virus and animal strains. The results of our
study do not indicate that the beneficial effects of L.
rhamnosus M21 are attributable to the modulation of IL-1
and IL-6 levels.
Previous reports have shown that protection against
influenza virus infection is accomplished with a biased Th1
response,23 and some probiotics have been known to
22 J.A. Song et al.modulate host Th1/Th2 balance.24 Thus, we examined
whether oral administration of L. rhamnosus M21 could
polarize the helper T cells response to Th1 following influ-
enza infection in mice. To investigate this hypothesis, we
verified the levels of IL-4 and IFN-g, representative cyto-
kines of Th1 and Th2 cells, in the lungs. Contrary to other
reports, we could not detect IL-4 in the lungs, as its levels
were too low to be measured (data not shown). Although
we could not explain the reason for the extremely low IL-4
levels, they persisted throughout repetitive studies.
Therefore, we focused on the changes in IFN-g levels in the
lungs. Even though the significant difference of IFN-g be-
tween the control group and the experiment group on Day 6
vanished, the level of IFN-g in the experimental group on
Day 3 was three times higher than that of the control group.
These results indicate that L. rhamnosus M21 could shift the
host to Th1 type, and these results were reinforced by the
increase in the levels of IL-12, another important Th1
cytokine. As shown in Fig. 5B, the IL-12 level was decreased
in the control group following virus infection, whereas it
was increased in the experimental group. IL-12 is one of the
important cytokines involved in immune responses, facili-
tating cellular immunity by enhancing the microbicidal
activities of macrophages and cytotoxic T lymphocytes. IL-
12 has profound regulatory effects on the immune system
through its ability to preferentially activate Th1 and natural
killer cells and to induce IFN-g production.25 The role of IL-
12 in fighting influenza virus infection has been addressed
previously.14,26 Yasui et al11 reported that orally adminis-
tered Lactobacillus casei Shirota, which exhibited anti-
influenza activities, enhanced IL-12 production in the
mediastinal lymph nodes and lungs, suggesting that the
beneficial effects of L. rhamnosus M21 are partially due to
enhanced IL-12 levels in the lung.
It should be noted that statistical significance in the IL-
12 and IFN-g levels between groups was observed only on a
specific date after challenge (e.g., on Day 1 for IL-12 and on
Day 3 for IFN-g). This can be explained by the kinetic
behavior of these cytokines. Both IL-12 and IFN-g are
antiviral cytokines that are secreted within a few hours
after viral invasion, and their early production is important
in controlling virus replication prior to the onset of adaptive
immune response. Treatment with L. rhamnosus M21
increased the early production of these cytokines, but this
effect subsided later. However, it is presumed that this
effect contributes to the host defense against viral
infection.
The importance of IgA in protective immunity against
influenza viral infections has also been previously
addressed. Renegar and Small27 showed that passive
transfer of IgA Ab could protect mice from intranasal
influenza virus infection, suggesting a pivotal role of IgA in
influenza immunity. An interesting feature in this context is
that probiotics that were administered orally could modu-
late the levels of sIgA in the lungs, and this phenomenon
can be explained as follows: orally administered probiotics
enter microfold (M) cells in the small intestine, where they
stimulate immune cells such as dendritic cells, macro-
phages, and lymphocytes. Activated B cells migrate to the
lungs through mucosal-associated tissues that secrete IgA.28
Influenza virus-specific IgA has been involved in neutralizing
the virus, whereas a nonspecific IgA prevents attachment ofthe virus to the mucosal surface.29 Therefore, for a pro-
biotic, with the aim of controlling influenza virus infection,
the increase of IgA level following administration is a crit-
ical feature. Indeed, L. rhamnosus M21-treated mice
showed significantly much higher levels of IgA in the lungs 6
days after the infection. These results support that of
Perdigo´n et al15, who showed that oral administration of
lactic acid bacteria increased the number of IgA þ cells in
bronchi. Although what we presented here were total IgA
levels, the influenza-specific IgA should play an important
role in improving the beneficial effects of orally adminis-
tered L. rhamnosus M21. Regrettably, we tried but failed to
detect the specific IgA in this study, and therefore, the
involvement of specific IgA remains in speculation.
In summary, our results show that L. rhamnosus M21
exhibits anti-influenza activity by shifting the host response
to Th1 type, enhancing IgA production as well as diminish-
ing the recruitment of inflammatory cells into the lungs, all
of which could contribute to lessening of lung pathologies.
In addition, considering the fact that L. rhamnosus M21 was
administered orally, other factors such as changes in the
gut environment should be considered for identifying the
underlying mechanisms. Interesting to note is that all pro-
biotics with anti-influenza activities do not exhibit the
same mechanisms as L. rhamnosus M21. Because a mixture
of several probiotics rather than a single probiotic produces
beneficial effects for various diseases,30 we can expect that
a combination of probiotics with similar anti-influenza ac-
tivities but with different mechanisms can compensate
each other’s drawbacks, thereby maximizing their activities
against influenza infection. Additional studies to address
this concept are in progress.
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